-
Mashup Score: 0Total antioxidant intake and prostate cancer in the Cancer of the Prostate in Sweden (CAPS) study. A case control study - BMC Cancer - 1 year(s) ago
Background The total intake of dietary antioxidants may reduce prostate cancer risk but available data are sparse and the possible role of supplements unclear. We investigated the potential association between total and dietary antioxidant intake and prostate cancer in a Swedish population. Methods We used FFQ data from 1499 cases and 1112 controls in the population based case–control study…
Source: BioMed CentralCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0FDA approves elacestrant for ER-positive - 1 year(s) ago
FDA approves elacestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
Categories: Hem/Oncs, Latest HeadlinesTweet-
This led to @FDAOncology approval Jan 27, 2023. https://t.co/LzDuY1TKNP #BrownJC #bcsm
-
-
Mashup Score: 0The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness - 1 year(s) ago
Vitamin C (ascorbic acid, AA) is a weak sugar acid structurally related to glucose. All known physiological and biochemical functions of AA are due to its action as an electron donor. Ascorbate readily undergoes pH-dependent autoxidation creating hydrogen peroxide (H2O2). In vitro evidence suggests that vitamin C functions at low concentrations as an antioxidant while high concentration is…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
Then @drdonsdizon walks us thru Hunyady J. The Result of Vitamin C Treatment of Patients with Cancer: Conditions Influencing the Effectiveness. Int J Mol Sci. 2022 Apr 15;23(8):4380. https://t.co/SLXHAvwLSq #BrownJC
-
-
Mashup Score: 0Breast/GYN Oncology Journal Club | January 4, 2023 - 1 year(s) ago
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Source: www.surveymonkey.comCategories: Hem/Oncs, Latest HeadlinesTweet-
If you joined us tonight, here’s the link for 1.0 AMA PRA Category 1 CME credit for #BrownJC Please note, you must complete the evaluation form electronically (within the survey monkey link below) to receive CME credit. https://t.co/YGCnmoo8M0
-
-
Mashup Score: 0CA-125 - Biomarker Kinetics™ - 1 year(s) ago
Modeled CA-125 KELIM™ in patients with stage III-IV high grade serous ovarian carcinomas treated with first line adjuvant chemotherapy
Source: www.biomarker-kinetics.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Required: At least 3 CA125 values during the 1st 100 days. KELIM was computed using an online calculator: https://t.co/jLX8RvGru8. (9/13) #BrownJC #gyncsm https://t.co/o07S69vsG9
-
-
Mashup Score: 1
Adjuvant abemaciclib reduces the risk of recurrence. The benefit is sustained beyond the completion of treatment with an absolute increase at 4 years, further supporting the use of abemaciclib in patients with high-risk hormone receptor-positive, HER2-negative early breast cancer. Further follow-up is needed to establish whether overall survival can be improved with abemaciclib plus endocrine…
Source: The Lancet OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Be sure to read the full article here! Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE) #BrownJC https://t.co/7CicovKBIW
-
-
Mashup Score: 2
Adjuvant abemaciclib combined with endocrine therapy (ET) previously demonstrated clinically meaningful improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) in hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer at the second interim analysis, however follow-up was limited. Here, we…
Source: Annals of OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
First thing first. MonarchE has previously been published after first interim analysis here: https://t.co/SKwdtR7EDv Definitely worth a read if you haven't already! #BrownJC
-
-
Mashup Score: 1FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer - 1 year(s) ago
PURPOSE The US Food and Drug Administration approved abemaciclib in combination with endocrine therapy (ET) for the adjuvant treatment of adult patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative, node-positive, early breast cancer (EBC) at high risk of recurrence and a Ki-67 score ≥ 20%. PATIENTS AND METHODS The approval was based on monarchE, a phase III,…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
And in case you missed it, the first analysis raised some questions.... 🤨 #ki67 #BrownJC FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer https://t.co/dszLagZyip
-
-
Mashup Score: 1
Still have questions about how to approach incorporating abemaciclib into the adjuvant treatment of breast cancer? Check out ASCO Guidelines Rapid Recommendation for Rapid Answers! @DrRFreedman @Dr…
Source: JCO Oncology PracticeCategories: Hem/Oncs, Latest HeadlinesTweet-
Some of us have even been trying to address those questions... #BrownJC Adjuvant Abemaciclib Plus Endocrine Therapy in the Treatment of High-Risk Early Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A https://t.co/IE8SzWUocm
-
-
Mashup Score: 0
PURPOSE In patients with high-grade ovarian cancer, predictors of bevacizumab efficacy in first-line setting are needed. In the ICON-7 trial, a poor tumor intrinsic chemosensitivity (defined by unfavorable modeled cancer antigen-125 [CA-125] ELIMination rate constant K [KELIM] score) was a predictive biomarker. Only the patients with high-risk disease (suboptimally resected stage III, or stage…
Source: Journal of Clinical OncologyCategories: Hem/Oncs, Latest HeadlinesTweet-
First, @drdonsdizon will present KELIM: Identification of Patients W/Ovarian Cancer Experiencing Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity: GOG-0218 Validation Study #BrownJC #gyncsm https://t.co/WLr1E22krR
-
It is interesting that antioxidants have such a complex relationship to cancer outcomes. Here's one example: https://t.co/qIfUjMyeun #BrownJC